Pain management in pancreatic cancer

Mariam Hameed, Haroon Hameed, Michael Erdek

Research output: Contribution to journalArticle

Abstract

A majority of pancreatic cancer patients present with pain at the time of diagnosis. Pain management can be challenging in light of the aggressive nature of this cancer. Apart from conventional pharmacotherapy, timely treatment with neurolytic celiac plexus block (NCPB) has been shown to be of benefit. NCPB has demonstrated efficacious pain control in high quality studies with analgesic effects lasting one to two months. NCPB has also shown to decrease the requirements of narcotics, and thus decrease opioid related side effects. Another option for the control of moderate to severe pain is intrathecal therapy (IT). Delivery of analgesic medications intrathecally allows for lower dosages of medications and thus reduced toxicity. Both of the above mentioned interventional procedures have been shown to have low complication rates, and be safe and effective. Ultimately, comprehensive pancreatic cancer pain management necessitates understanding of pain mechanisms and delivery of sequential validated therapeutic interventions within a multidisciplinary patient care model.

Original languageEnglish (US)
Pages (from-to)43-60
Number of pages18
JournalCancers
Volume3
Issue number1
DOIs
StatePublished - Mar 2011

Fingerprint

Celiac Plexus
Pain Management
Pancreatic Neoplasms
Pain
Analgesics
Narcotics
Opioid Analgesics
Patient Care
Therapeutics
Drug Therapy
Neoplasms

Keywords

  • Intrathecal therapy
  • Neurolytic celiac plexus block
  • Opioids
  • Pain
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pain management in pancreatic cancer. / Hameed, Mariam; Hameed, Haroon; Erdek, Michael.

In: Cancers, Vol. 3, No. 1, 03.2011, p. 43-60.

Research output: Contribution to journalArticle

Hameed, Mariam ; Hameed, Haroon ; Erdek, Michael. / Pain management in pancreatic cancer. In: Cancers. 2011 ; Vol. 3, No. 1. pp. 43-60.
@article{389278c2e441477a9e3270f0c93a5fd4,
title = "Pain management in pancreatic cancer",
abstract = "A majority of pancreatic cancer patients present with pain at the time of diagnosis. Pain management can be challenging in light of the aggressive nature of this cancer. Apart from conventional pharmacotherapy, timely treatment with neurolytic celiac plexus block (NCPB) has been shown to be of benefit. NCPB has demonstrated efficacious pain control in high quality studies with analgesic effects lasting one to two months. NCPB has also shown to decrease the requirements of narcotics, and thus decrease opioid related side effects. Another option for the control of moderate to severe pain is intrathecal therapy (IT). Delivery of analgesic medications intrathecally allows for lower dosages of medications and thus reduced toxicity. Both of the above mentioned interventional procedures have been shown to have low complication rates, and be safe and effective. Ultimately, comprehensive pancreatic cancer pain management necessitates understanding of pain mechanisms and delivery of sequential validated therapeutic interventions within a multidisciplinary patient care model.",
keywords = "Intrathecal therapy, Neurolytic celiac plexus block, Opioids, Pain, Pancreatic cancer",
author = "Mariam Hameed and Haroon Hameed and Michael Erdek",
year = "2011",
month = "3",
doi = "10.3390/cancers3010043",
language = "English (US)",
volume = "3",
pages = "43--60",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - Pain management in pancreatic cancer

AU - Hameed, Mariam

AU - Hameed, Haroon

AU - Erdek, Michael

PY - 2011/3

Y1 - 2011/3

N2 - A majority of pancreatic cancer patients present with pain at the time of diagnosis. Pain management can be challenging in light of the aggressive nature of this cancer. Apart from conventional pharmacotherapy, timely treatment with neurolytic celiac plexus block (NCPB) has been shown to be of benefit. NCPB has demonstrated efficacious pain control in high quality studies with analgesic effects lasting one to two months. NCPB has also shown to decrease the requirements of narcotics, and thus decrease opioid related side effects. Another option for the control of moderate to severe pain is intrathecal therapy (IT). Delivery of analgesic medications intrathecally allows for lower dosages of medications and thus reduced toxicity. Both of the above mentioned interventional procedures have been shown to have low complication rates, and be safe and effective. Ultimately, comprehensive pancreatic cancer pain management necessitates understanding of pain mechanisms and delivery of sequential validated therapeutic interventions within a multidisciplinary patient care model.

AB - A majority of pancreatic cancer patients present with pain at the time of diagnosis. Pain management can be challenging in light of the aggressive nature of this cancer. Apart from conventional pharmacotherapy, timely treatment with neurolytic celiac plexus block (NCPB) has been shown to be of benefit. NCPB has demonstrated efficacious pain control in high quality studies with analgesic effects lasting one to two months. NCPB has also shown to decrease the requirements of narcotics, and thus decrease opioid related side effects. Another option for the control of moderate to severe pain is intrathecal therapy (IT). Delivery of analgesic medications intrathecally allows for lower dosages of medications and thus reduced toxicity. Both of the above mentioned interventional procedures have been shown to have low complication rates, and be safe and effective. Ultimately, comprehensive pancreatic cancer pain management necessitates understanding of pain mechanisms and delivery of sequential validated therapeutic interventions within a multidisciplinary patient care model.

KW - Intrathecal therapy

KW - Neurolytic celiac plexus block

KW - Opioids

KW - Pain

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=79953712023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953712023&partnerID=8YFLogxK

U2 - 10.3390/cancers3010043

DO - 10.3390/cancers3010043

M3 - Article

C2 - 24212605

AN - SCOPUS:79953712023

VL - 3

SP - 43

EP - 60

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 1

ER -